Trial Profile

A Phase Ib/II Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-muscle Invasive Bladder Cancer

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 25 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALT 801 (Primary) ; Gemcitabine
Indications Bladder cancer
Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
Sponsors Altor BioScience Corporation

Most Recent Events

19 Jul 2024 Status changed from active, no longer recruiting to discontinued. (The study was terminated early due to low enrollment.)
07 Jan 2019 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified January 2017).
23 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2018.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com